ClinicalTrials.gg
Not yet recruitingNCT07683793Updated Jul 6, 2026

A Study to Compare How CHF10196 (Florensocatib) is Absorbed Into the Blood When Given Alone and With a Drug That Reduces Stomach Acid in Healthy Male Participants

A Phase 1 interventional study of CHF10196 and Pantoprazole in Healthy Volunteers, sponsored by Chiesi Farmaceutici S.p.A.. Not yet recruiting at 1 site in United Kingdom. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This Phase 1 study evaluates the effect of pantoprazole (a proton pump inhibitor) on the pharmacokinetics (PK) of CHF10196 (Florensocatib) in healthy male participants. Participants receive CHF10196 alone and in combination with pantoprazole to assess potential drug-drug interaction (DDI) effects on systemic exposure.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • pharmacokinetics
  • CHF10196
  • DDI
  • Dipeptidyl Peptidase 1 (DPP1) inhibitor
03

In context

Lead sponsor

Chiesi Farmaceutici S.p.A. is the lead sponsor of 185 studies on the registry; 22 are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 11 (61%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • (body mass index) between 18.0 and 30.0 kg/m²
  • Weight between 45 and 100 kg
  • Non-smokers or ex-smokers (\<5 pack-years)
  • Clinically healthy based on medical history and examination
  • Normal vital signs
  • Normal
  • Willingness to comply with requirements

Key Exclusion Criteria:

  • Recent participation in another clinical study
  • Significant medical conditions
  • Abnormal laboratory values
  • Positive or hepatitis tests
  • Recent infection or COVID-19
  • Drug or alcohol abuse
  • Use of prohibited medications
  • Gastrointestinal surgery affecting absorption
  • to study drugs
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Fixed Sequence Treatment

    CHF10196 - Pantoprazole - Pantoprazole with CHF10196

    Drug: CHF10196 · Drug: Pantoprazole

Interventions

  • Treatment Period 1: CHF10196 single dose administration on Day1; Treatment Period 2: CHF10196 single dose administration after pantoprazole single dose administration on Day13

  • Treatment Period 2: Pantoprazole single dose administration from Day8 to Day13

06

What researchers measure

Primary outcomes

  1. PK parameter: AUC0-∞

    comparing the ratio of adjusted geometric means for area under the concentration time curve from time 0 extrapolated to infinity (AUC0-∞) when CHF10196 administered alone and when administered with pantoprazole

    Time frame: pre-dose up to 168 hours post-dose

  2. PK parameter: AUC0-t

    comparing the ratio of adjusted geometric means for area under the plasma concentration time curve from time 0 to last quantifiable concentration (AUC0-t) when CHF10196 administered alone and when administered with pantoprazole

    Time frame: pre-dose up to 168 hours post-dose

  3. PK parameter: Cmax

    comparing the ratio of adjusted geometric means for maximum observed concentration when CHF10196 administered alone and when administered with pantoprazole

    Time frame: pre-dose up to 168 hours post-dose

Secondary outcomes

  1. Safety and tolerability: Incidence of adverse events (AE)

    Number and percentage of adverse events (AE) when CHF10196 administered alone and when administered with pantoprazole

    Time frame: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2

  2. Safety and tolerability: Change from baselines for vital signs: PR

    Mean changes from baselines to each post-dose timepoint in PR (pulse rate), by treatment period (TP). Baselines (the last value before the first administration of any CHF10196 of each TP or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196)

    Time frame: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2

  3. Safety and tolerability: Change from baselines for vital signs - RR

    Mean changes from baselines to each post-dose timepoint in vital signs: RR (respiratory rate) by treatment period (TP). Baselines (the last value before the first administration of any CHF10196 of each TP or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196)

    Time frame: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2

  4. Safety and tolerability: Change from baselines for vital signs - blood pressure

    Mean changes from baselines to each post-dose timepoint in vital signs (Systolic Blood Pressure and Diastolic Blood Pressure) by treatment period (TP). Baselines (the last value before the first administration of any CHF10196 of each TP or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196)

    Time frame: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2

  5. Safety and tolerability: Change from baselines for ECG

    change from baselines in milliseconds (ms). Intervals recorded: PR , RR, QT, QTc, QRS duration, QTcF (Fridericia-corrected QT interval Baselines (the last value before the first administration of any CHF10196 of each treatment period (TP) or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196

    Time frame: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2

  6. Safety and tolerability: Change from baseline for ECG (HR)

    change from baseline for ECG recording of heart rate (HR) Baselines (the last value before the first administration of any CHF10196 of each Treatment Period (TP) or pantoprazole (TP2 only). In TP2, two separate baselines will be derived relative to pantoprazole and CHF10196).

    Time frame: Day 1 to Day 7 for treatment period 1 and Day 8 to Day 19 for treatment period 2

  7. Safety and tolerability: Change from baseline for laboratory abnormalities

    Number of participants with abnormal blood laboratory test results. Quantitative laboratory parameters (chemistry and haematology) will be summarised by treatment as absolute value and change from baseline using descriptive statistics

    Time frame: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2

  8. Additional pharmacokinetic parameters: AUC0-24h

    comparing the ratio of adjusted geometric means for the area under the plasma concentration time curve from time 0 to 24 h post-dose when CHF10196 administered alone and when administered with pantoprazole (with their 90% two-sided Confidence Intervals)

    Time frame: From Day 1 to Day 2 for treatment period 1; from Day 13 to Day 14 for treatment period 2

  9. Additional pharmacokinetic parameters: CL/F

    comparing the total body clearance (CL/F) by treatment period using descriptive statistics

    Time frame: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2

  10. Additional pharmacokinetic parameters: t1/2

    comparing the terminal half-life (t1/2) by treatment period using descriptive statistics

    Time frame: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2

  11. Additional pharmacokinetic parameters: Vd/F

    comparing the apparent volume of distribution (Vd/F) by treatment period using descriptive statistics

    Time frame: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2

  12. Additional pharmacokinetic parameters: tmax

    Evaluating the Hodges-Lehmann non-parametric estimate of location shift between CHF10196 with pantoprazole (test) and CHF10196 alone (reference) in median time corresponding to maximum plasma when CHF10196 administered alone and when administered with pantoprazole concentration (tmax)

    Time frame: From baseline (Day -1) to Day 8 for treatment period 1; from Day 8 to Day 20 for treatment period 2

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Chiesi clinical data sharing scope, process and data access criteria is available on the Chiesi Group website

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Dec 2026, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2026
First posted
Jul 6, 2026
StartEst.
Oct 14, 2026
Primary completionEst.
Dec 9, 2026
CompletionEst.
Dec 9, 2026
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07683793
Responsible party
Sponsor
First posted
Jul 6, 2026
Start date
Oct 14, 2026 (estimated)
Primary completion
Dec 9, 2026 (estimated)
Completion
Dec 9, 2026 (estimated)
Last update
Jul 6, 2026

Study contacts

Chiesi Clinical trial Info
Contact
clinicaltrials_info@chiesi.com
+390521279715
Benjamen Monaghan
principal investigator · Fortrea Clinical Research Unit (CRU)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Florensocatib

Start the discussion